Recent emphasis on elimination and eradication (E&E) goals for malaria programs is changing the way experts evaluate malaria diagnostic tools and tactics. As malaria prevalence is driven to lower levels, the focus pivots toward low-density, subclinical infections and geographically and demographically concentrated reservoirs. The proportions of species and subspecies found in these reservoirs may also change in favor of higher fitness phenotypes that are more difficult to diagnose and treat. These changes present both threats and opportunities to existing diagnostic technologies and those in the development pipeline. Furthermore, the evolution of new tactics to combat malaria in low-prevalence areas necessitates a review of technologies in the product development pipeline to encourage development of appropriate tools for new diagnostics use-scenarios. In light of shifting goals, epidemiology, and tactics, this report focuses on enzyme linked immunosorbent assays (ELISA) for histidine-rich protein 2 (HRP 2) for Plasmodium falciparum (P. falciparum) detection.